Highest-materiality recent filing
Q2 revenue $15.0B (+1% operational); launched/acquired products grew 18% operationally.
Pfizer CFO Dave Denton to step down Aug 15; Cecile Guegan named interim CFO
Dave Denton to step down as CFO effective August 15, 2026, for a consumer goods opportunity.
Pfizer Q1 revenue $14.5B (+2% op); adj EPS $0.75 (-18%); reaffirms FY26 guidance
Revenue $14.45B, up 2% operationally; ex-COVID products grew 7% op; launched/acquired products up 22% op.
Pfizer reports FY2025 revenue $62.6B, adj. EPS $3.22; reaffirms FY2026 guidance
Full-year 2025 revenue $62.6B (-2% operational); non-COVID portfolio +6% operational.
Pfizer revises FY2025 revenue to ~$62B (from $61-64B), provides FY2026 EPS guidance $2.80-3.00
Revised FY2025 revenue guidance to ~$62.0B from prior $61-64B; reaffirmed adjusted diluted EPS $3.00-3.15.
Pfizer completes $6.0 billion offering of notes due 2027-2065
Issued $500M Floating Rate Notes due 2027, $1B 3.875% Notes due 2027, $1B 4.200% Notes due 2030
Pfizer completes $7B acquisition of Metsera, including contingent milestones up to $20.65/sh
Enterprise value ~$7.0B; each Metsera share converted into $65.60 cash at closing.
Q3 revenues $16.7B (-7% operational YoY); reported EPS $0.62, adj EPS $0.87.
Pfizer Q2 2025 revenue $14.7B (+10% YoY); raises FY adjusted EPS guidance to $2.90-$3.10
Reported diluted EPS $0.51; adjusted diluted EPS $0.78, up 30% YoY.
Pfizer subsidiary completes €3.3B debt offering in four tranches
Issued €750M 2.875% notes due 2029, €1B 3.250% notes due 2032, €750M 3.875% notes due 2037, €800M 4.250% notes due 2045.
Pfizer Q1 revenues $13.7B (-8% YoY), adjusted EPS $0.92 (+12%); reaffirms FY2025 guidance
Q1 revenues $13.7B, down 8% YoY; reported diluted EPS $0.52 (down 5%), adjusted diluted EPS $0.92 (up 12%).
Pfizer Q4/FY2024 rev $63.6B (+7% op); adj EPS $3.11; reaffirms 2025 guidance
FY2024 revenues $63.6B (+7% operational); excluding COVID products, up 12% operationally.
Pfizer provides 2025 revenue guidance $61-64B, adj. EPS $2.80-3.00
Full-year 2025 revenue guidance range of $61.0 to $64.0 billion, with operational growth approximately flat to 5% year-over-year.
Pfizer Q3 revenue $17.7B (+32% YoY); raises FY 2024 guidance on revenue and EPS
Q3 2024 revenues of $17.7B, operational growth +32% YoY; ex-Paxlovid/Comirnaty revenue up 14% operationally.
Pfizer Q2 adj EPS $0.60, revenue $13.3B; raises FY2024 guidance
Revenues $13.3B, +2% YoY (+3% operational); non-COVID revenue grew 14% operationally.
Pfizer begins external search for successor to Chief Scientific Officer Mikael Dolsten
CSO and President of R&D Mikael Dolsten to step down after over 15 years; external search launched.
Pfizer launches multi-year COGS reduction program; targets $1.5B savings by 2027
First phase of cost-reduction program expected to deliver ~$1.5B savings by end of 2027.
Pfizer Q1 revenue $14.9B (-20% YoY); adj. EPS $0.82; raises FY adj. EPS guidance
Q1 revenue $14.9B, operational decline 19% YoY; ex-COVID products grew 11% operationally.
Pfizer posts FY2023 revenue $58.5B, adj EPS $1.84; reaffirms FY2024 guidance
Full-year 2023 revenues $58.5B, down 41% operationally; reported diluted EPS $0.37, down 93%; adjusted diluted EPS $1.84, down 72%.
Pfizer completes $43B acquisition of Seagen; Seagen becomes wholly owned subsidiary
Acquisition closed Dec 14, 2023; $229 per share in cash for total enterprise value approx. $43 billion.
Pfizer completes $43B acquisition of Seagen at $229/share, expanding oncology portfolio
Pfizer acquired Seagen for $229 per share in cash, total enterprise value of ~$43 billion.
Pfizer guides FY2024 rev $58.5-61.5B, adj EPS $2.05-2.25; Seagen closing Dec 14
FY2024 revenue guidance $58.5-$61.5B; includes ~$8B from Comirnaty/Paxlovid and ~$3.1B from Seagen.
Pfizer expects to close Seagen acquisition on Dec 14; all regulatory approvals received
Expects to close Seagen acquisition on Dec 14, 2023 after receiving all required regulatory approvals.
Pfizer Q3 revenue $13.2B (-42% YoY), adjusted LPS $(0.17) on $5.6B write-off; reaffirms FY guidance
Q3 revenues $13.2B, down 41% operationally; non-COVID products grew 10% operationally.
Pfizer cuts FY2023 revenue guide by $9B, records $5.5B COVID write-off, amends Paxlovid deal
Revises 2023 revenue to $58-61B (from $67-70B); Paxlovid revenues cut ~$7B including $4.2B reversal.
Pfizer Q2 revenues $12.7B (-54% YoY); narrows FY revenue guidance to $67-70B
Q2 reported diluted EPS $0.41 (-77% YoY); adjusted diluted EPS $0.67 (-67% YoY).
Pfizer completes $31B multi-tranche note offering to fund Seagen acquisition
Issued $31B aggregate principal across 8 tranches: 2025-2063 maturities, rates 4.45%-5.34%.
Pfizer Q1 revenue falls 29% to $18.3B; adjusted EPS $1.23; reaffirms FY2023 guidance
First-quarter 2023 revenues $18.3B (down 29% YoY); reported diluted EPS $0.97, adjusted diluted EPS $1.23 (down 24% YoY).
Pfizer acquires Seagen for $229/share in $43B cash deal to boost oncology
Acquisition of Seagen for $229 per share in cash; total enterprise value approximately $43 billion.
Full-year 2022 revenues $100.3B (record), up 23% YoY; reported EPS $5.47, adjusted EPS $6.58.
Pfizer Q3 revenue $22.6B (-6% YoY); Adj. EPS $1.78 (+40%); raises FY2022 guidance
Reported diluted EPS $1.51 (+6%); Adjusted diluted EPS $1.78 (+40%) YoY.
Pfizer Q2 revenue $27.7B record; adj. EPS $2.04 (+92%); raises FY guidance $0.24
Q2 revenue $27.7B (+47% YoY, +53% operational); Paxlovid contributed $8.1B, Comirnaty +20% operationally.
Pfizer acquires Biohaven for $11.6B cash; gains migraine portfolio NURTEC ODT
Total consideration ~$11.6B: $148.50/share cash + 0.5 share of New Biohaven per Biohaven share.
Revenues $25.7B up 82% operationally; ex-COVID products +2% operational growth.
Pfizer changes non-GAAP measure to include IPR&D costs; Q1 adj. income seen down ~$275M
Starting Q1 2022, acquired IPR&D costs (upfront/milestone payments, asset acquisitions) included in Adjusted income; prior periods recast.
Pfizer names David M. Denton as CFO effective May 2, 2022
David M. Denton named CFO, EVP effective May 2, 2022, succeeding Frank D'Amelio after 15-year career.
the Company announced that Cecile Guegan, the Company’s Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer, effective August 16, 2026
Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026
elected Mortimer J. Buckley to serve as a member of the Company’s Board, effective immediately.
On July 9, 2024, Pfizer Inc. (the "Company") announced that it is beginning the process of finding a successor for Dr. Mikael Dolsten, the Company’s Chief Scientific Officer and President, Pfizer Research & Development after his more than 15-year distinguished career with the Company.
elected Cyrus Taraporevala to serve as a member of the Company’s Board, effective immediately.
the Pfizer International Commercial Division, which will be led by Alexandre de Germay, who will join Pfizer as Chief International Commercial Officer, Executive Vice President, and will report to Dr. Bourla.
the Pfizer U.S. Commercial Division, which will be led by Aamir Malik, who will become Chief U.S. Commercial Officer, Executive Vice President, and continue reporting to Dr. Bourla
As a result of this reorganization, the role currently held by Angela Hwang, Chief Commercial Officer, Executive Vice President, is being eliminated and she will cease serving in her current role and as a member of the Company’s Executive Leadership Team effective as of December 15, 2023.
Pfizer will create an end-to-end business organization called Pfizer Oncology Division, which will integrate certain Oncology Commercial and R&D operations from both Pfizer and Seagen and will be led by Dr. Chris Boshoff, who will become Chief Oncology Officer, Executive Vice President, and continue reporting to Dr. Albert Bourla, Chairman and Chief Executive Officer.
As a result of this reorganization, the role held by Dr. William Pao, Chief Development Officer, Executive Vice President, is being eliminated and he will leave the Company effective August 15, 2023.
Effective immediately, Dr. Chris Boshoff, currently Chief Development Officer – Oncology, will become Chief Oncology Research and Development Officer, Executive Vice President
As previously reported by the Company in a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 19, 2021, the Company announced that Frank D’Amelio will be leaving his position as Chief Financial Officer and Executive Vice President after a nearly 15-year distinguished career with the Company and that Mr. D’Amelio would continue to serve as CFO until the appointment of a new chief financial officer, and will stay on as a special advisor until as late as December 31, 2022 in order to ensure a smooth transition of his CFO responsibilities.
Max materiality 1.00 · Median 0.75 · Most common event earnings